GSK reports ‘clinically meaningful’ overall survival results from RUBY trial

GSK plc over the weekend announced “statistically significant and clinically meaningful” overall survival, or OS, results from Part 1 and progression-free survival, or PFS, results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial in adult patients with primary advanced or recurrent endometrial cancer. These data were presented in a late-breaking plenary session at the Society of Gynecologic Oncology 2024 Annual Meeting on Women’s Cancer held March 16-18, the company noted. Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK said: “The positive data presented today further show how dostarlimab-based regimens could benefit a broader set of patients with endometrial cancer. The results we’ve seen to date comprise the growing body of evidence supporting the role of dostarlimab as the backbone of our immuno-oncology development programme. Our goal is to continue to identify ways to use dostarlimab alone and in combination with other therapies to help improve outcomes for patients with limited treatment options.”